Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane A Foster

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
CNS Spectrums|May 23, 2023
Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 reportM Ishrat Husain, Jane A Foster, Brittany L Mason, et al.
Translational Psychiatry|August 22, 2021
Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant responseLaura M Fiori, Massimiliano Orri, Zahia Aouabed, et al.
Pharmacopsychiatry|July 6, 2022
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) StudyHelena K Kim, Gwyneth Zai, Daniel J Müller, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 21, 2023
Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: A CAN-BIND-1 reportRaegan Mazurka, Simone Cunningham, Stefanie Hassel, et al.
JAMA Network Open|August 4, 2025
Latent Profile Analysis of Childhood Maltreatment and Neural Markers in DepressionJessica Rowe, Nikita Nogovitsyn, Raegan Mazurka, et al.
BMC Psychiatry|June 4, 2020
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocolJennifer L Phillips, Natalia Jaworska, Elizabeth Kamler, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 20, 2020
Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxineVictoria S Marshe, Farhana Islam, Malgorzata Maciukiewicz, et al.
Psychological Medicine|August 25, 2022
Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 reportMehri Sajjadian, Rudolf Uher, Keith Ho, et al.
Journal of Psychiatric Research|April 5, 2026
The association between body mass index and treatment outcomes in major depressive disorder: a CAN-BIND-1 studyHelena K Kim, Brett D M Jones, Margaret K Hahn, et al.
Psychiatry Research|June 3, 2025
Symptom network connectivity indices as predictors of relapse in major depressive disorderAbraham Nunes, Barbara Pavlova, John-Jose Nuñez, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
CNS Spectrums|May 23, 2023
Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 reportM Ishrat Husain, Jane A Foster, Brittany L Mason, et al.
Translational Psychiatry|August 22, 2021
Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant responseLaura M Fiori, Massimiliano Orri, Zahia Aouabed, et al.
Pharmacopsychiatry|July 6, 2022
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) StudyHelena K Kim, Gwyneth Zai, Daniel J Müller, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 21, 2023
Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: A CAN-BIND-1 reportRaegan Mazurka, Simone Cunningham, Stefanie Hassel, et al.
JAMA Network Open|August 4, 2025
Latent Profile Analysis of Childhood Maltreatment and Neural Markers in DepressionJessica Rowe, Nikita Nogovitsyn, Raegan Mazurka, et al.
BMC Psychiatry|June 4, 2020
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocolJennifer L Phillips, Natalia Jaworska, Elizabeth Kamler, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 20, 2020
Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxineVictoria S Marshe, Farhana Islam, Malgorzata Maciukiewicz, et al.
Psychological Medicine|August 25, 2022
Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 reportMehri Sajjadian, Rudolf Uher, Keith Ho, et al.
Journal of Psychiatric Research|April 5, 2026
The association between body mass index and treatment outcomes in major depressive disorder: a CAN-BIND-1 studyHelena K Kim, Brett D M Jones, Margaret K Hahn, et al.
Psychiatry Research|June 3, 2025
Symptom network connectivity indices as predictors of relapse in major depressive disorderAbraham Nunes, Barbara Pavlova, John-Jose Nuñez, et al.
Pageof 14